The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

• Автори: Gabriella Giancane (Автор), Claudio Lavarello (Автор), Angela Pistorio (Автор), Sheila K. Oliveira (Автор), Francesco Zulian (Автор), Ruben Cuttica (Автор), Michel Fischbach (Автор), Bo Magnusson (Автор), Serena Pastore (Автор), Roberto Marini (Автор), Silvana Martino (Автор), Anne Pagnier (Автор), Christine Soler (Автор), Valda Staņēvicha (Автор), Rebecca Ten Cate (Автор), Yosef Uziel (Автор), Jelena Vojinovic (Автор), Elena Fueri (Автор), Angelo Ravelli (Автор), Alberto Martini (Автор), Nicolino Ruperto (Автор), for the Paediatric Rheumatology International Trials Organisation (PRINTO) (Автор)
• Формат: Книга
• Опубліковано: BMC, 2019-05-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract Background Prednisone (PDN) in juvenile dermatomyositis (JDM), alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represents the first-line treatment option for new onset JDM patients. No clear evidence based guidelines are actually...